Incyte Corporation Share Price and Company Fundamentals



Price
$69
Change
-0.780 (-1.118%)
52 week
68.63 - 101.47

Last traded: Today at 8:00 PM

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Key Metrics

PE ratio

45.36

PB ratio

5.18

Dividend yield

Beta

0.75

Market cap

$15.24B

Enterprise value

$13.35B

Company profile

Industry / SectorBiotechnology / Healthcare
Full time employees1773
Websitehttp://www.incyte.com
Mailing address1801 Augustine Cut-Off Wilmington DE 19803 United States
Phone / Fax302 498 6700 /

Dividends

Incyte Corporation does not pay dividends.

Company Executives

As of Sep 2021, following are the company executives and directors listed on Incyte Corporation.

NameTitleAgeTotal Pay
Mr. Herve HoppenotChairman, Pres & CEO602.55M
Ms. Christiana StamoulisExec. VP & CFO49989.39k
Dr. Vijay K. Iyengar M.D.Exec. VP of Global Strategy & Corp. Devel.47945.9k
Dr. Barry P. Flannelly M.B.A., Pharm.D., MBAExec. VP & GM of North America62833.63k
Dr. Steven H. SteinExec. VP & Chief Medical Officer53967.8k
Mr. Michael James MorrisseyExec. VP & Head of Global Technical Operations56
Dr. Dashyant Dhanak Ph.D.Exec. VP & Chief Scientific Officer59
Ms. Christine ChiouHead of Investor Relations
Ms. Maria E. PasqualeExec. VP & Gen. Counsel54
Ms. Pamela M. MurphyVP of Investor Relations & Corp. Communications69

Profitability and management effectiveness

Profit margin

12.41%

Operating margin

15.76%

Return on assets

7.53%

Return on equity

12.79%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Incyte Corporation is 15.24B and its enterprise value is 13.35B. The enterprise value to revenue ratio of INCY is 4.91.

The INCY's stocks Beta value is 0.75 making it 25% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Incyte Corporation (NASDAQ:INCY) Frequently Asked Questions

1. What is Incyte Corporation's Stock Symbol?

Incyte Corporation trades on NASDAQ under the ticker symbol "INCY".

2. What is Incyte Corporation's stock price today?

One share of INCY stock can currently be purchased for approximately $69.

3. How can I contact Incyte Corporation?

Incyte Corporation's mailing address is 1801 Augustine Cut-Off Wilmington DE 19803 United States. The company can be reached via phone at 302 498 6700.

4. What is Incyte Corporation's official website?

The official website of Incyte Corporation is http://www.incyte.com.